These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 2828894)
61. Feasibility of prophylaxis and therapy against gram-negative infections by human monoclonal antibodies. Lang AB; Fürer E; Cryz SJ FEMS Immunol Med Microbiol; 1993 Jun; 7(1):9-13. PubMed ID: 8364527 [TBL] [Abstract][Full Text] [Related]
62. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Sawa T; Ito E; Nguyen VH; Haight M Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637 [TBL] [Abstract][Full Text] [Related]
64. Stability of specific immunoglobulin secretion by EBV-transformed lymphoblastoid cells and human-murine heterohybridomas. Glasky MS; Reading CL Hybridoma; 1989 Aug; 8(4):377-89. PubMed ID: 2550358 [TBL] [Abstract][Full Text] [Related]
65. Protection of mice against P. aeruginosa infections by large-scale affinity-purified human IgG specific to P. aeruginosa outer membrane proteins. Lee NG; Jung SB; Ahn BY; Kim YG; Lee Y; Jeon YJ; Park WJ Vaccine; 1999 Nov; 18(7-8):665-74. PubMed ID: 10547426 [TBL] [Abstract][Full Text] [Related]
66. Common protective antigen between Pseudomanas aeruginosa and Vibrio cholerae. Yamamoto A; Homma JY; Ghoda A; Ishihara T; Takeuchi S Jpn J Exp Med; 1979 Dec; 49(6):383-90. PubMed ID: 120454 [TBL] [Abstract][Full Text] [Related]
67. A polyreactive human anti-lipid A monoclonal antibody having cross reactivity to polysaccharide portions of Pseudomonas aeruginosa lipopolysaccharides. Yokota S; Ohtsuka H; Kohzuki T; Noguchi H FEMS Immunol Med Microbiol; 1996 May; 14(1):31-8. PubMed ID: 8804973 [TBL] [Abstract][Full Text] [Related]
68. Human monoclonal antibodies to a genus-specific chlamydial antigen, produced by EBV-transformed B cells. Rosén A; Persson K; Klein G J Immunol; 1983 Jun; 130(6):2899-902. PubMed ID: 6189902 [TBL] [Abstract][Full Text] [Related]
69. Specific and nonspecific imaging of localized Fisher immunotype 1 Pseudomonas aeruginosa infection with radiolabeled monoclonal antibody. Rubin RH; Young LS; Hansen WP; Nedelman M; Wilkinson R; Nelles MJ; Callahan R; Khaw BA; Strauss HW J Nucl Med; 1988 May; 29(5):651-6. PubMed ID: 3131499 [TBL] [Abstract][Full Text] [Related]
70. [Investigation on the protection of mice from infection with Pseudomonas aeruginosa using monoclonal antibodies]. Ye DN; Wang CX; Yan RH; Dai BM; Ni HY Sichuan Yi Xue Yuan Xue Bao; 1985 Sep; 16(3):188-90. PubMed ID: 3939267 [No Abstract] [Full Text] [Related]
71. Pharmacokinetics of an IgM human monoclonal antibody against Pseudomonas aeruginosa in nonseptic patients. Meng YG; Wong T; Saravolatz LD; Pennington JE J Infect Dis; 1993 Mar; 167(3):784-5. PubMed ID: 8440953 [No Abstract] [Full Text] [Related]
72. [Therapeutic effects of anti-OEP-antibodies in the Pseudomonas aeruginosa (Fisher's seven serotypes) infection of mice and the influence of this antibody upon the phagocytic activity of mice spleen macrophages (author's transl)]. Haranaka K; Satomi N; Matsuo M; Kunii O; Mashimo K Kansenshogaku Zasshi; 1979 Apr; 53(4):175-81. PubMed ID: 89175 [No Abstract] [Full Text] [Related]
73. A protective human monoclonal IgA antibody produced in vitro: anti-pneumococcal antibody engendered by Epstein-Barr virus-immortalized cell line. Steinitz M; Tamir S; Ferne M; Goldfarb A Eur J Immunol; 1986 Feb; 16(2):187-93. PubMed ID: 3007166 [TBL] [Abstract][Full Text] [Related]
74. Live, attenuated vaccines against Pseudomonas: observations in the experimental animal and the human. Bellanti JA; Sordelli DO; Cerquetti MC; Wan KS; Arias G; Cereb N; Zuba D; Kulczycki L; Hooke AM Ann Sclavo Collana Monogr; 1986; 3(1-2):247-58. PubMed ID: 3122803 [No Abstract] [Full Text] [Related]
75. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa. Collins MS; Ladehoff DK; Mehton NS; Noonan JS FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368 [TBL] [Abstract][Full Text] [Related]
76. Characterization of the antibody response in inbred mice to a high-molecular-weight polysaccharide from Pseudomonas aeruginosa immunotype 1. Markham RB; Pier GB Infect Immun; 1983 Jul; 41(1):232-6. PubMed ID: 6407998 [TBL] [Abstract][Full Text] [Related]
77. [Antibodies against Pseudomonas aeruginosa toxin in preparations of normal human immunoglobulin]. Ianishevskaia MN; Kuz'mina NS; Kutimova LR; Lents MN; Minakova LV Zh Mikrobiol Epidemiol Immunobiol; 1983 Jun; (6):100-3. PubMed ID: 6412489 [TBL] [Abstract][Full Text] [Related]
78. [A human monoclonal antibody cocktail for experimental mouse infection with clinically isolated strains of Pseudomonas aeruginosa]. Miura S; Ishibashi Y; Arai T Kansenshogaku Zasshi; 1993 Dec; 67(12):1167-71. PubMed ID: 8294765 [TBL] [Abstract][Full Text] [Related]
79. EBV transformation and microfusion as the potential source of human monoclonal antisperm antibodies. Kurpisz M; Simon LL; Alexander NJ Am J Reprod Immunol Microbiol; 1987 Oct; 15(2):61-5. PubMed ID: 2829635 [TBL] [Abstract][Full Text] [Related]
80. Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat. Landsperger WJ; Kelly-Wintenberg KD; Montie TC; Knight LS; Hansen MB; Huntenburg CC; Schneidkraut MJ Infect Immun; 1994 Nov; 62(11):4825-30. PubMed ID: 7927761 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]